Kineta Inc
KA
Get informed when a big investor buys or sells
+ FollowMarket Cap$7.05M
Close$
Share Statistics
| Market cap | $7.05 Million |
|---|---|
| Enterprise Value | $12.26 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1.42 |
| Beta | 0.57 |
| Outstanding Shares | 12,902,000 |
Return
| Return on Equity | 58.35% |
|---|---|
| Return on Assets | -914.25% |
| Return on Invested Capital | 64.34% |
Valuation & Multiples
| P/E Ratio | -2.24 |
|---|---|
| PEG | 2.68 |
| Price to Sales | - |
| Price to Book Ratio | -0.29 |
| Enterprise Value to Revenue | 2.83 |
| Enterprise Value to EBIT | -1.44 |
| Enterprise Value to Net Income | -2 |
| Total Debt to Enterprise | 0.45 |
| Debt to Equity | -0.42 |
Revenue Sources
No data
Insider Trades
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Kineta Inc
45 employees
CEO: Meenu Chhabra Yumanity Therapeutics is a clinical-stage biopharmaceutical company dedicated to accelerating the revolution in the treatment of neurodegenerative diseases through its scientific foundation and drug discovery platform. The Company's most...